TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34558200

Group type: COMPARATOR
Intervention: Milvexian (4, 20, 60, 200, 300, or 500 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Milvexian (once- or twice-daily for 14 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Milvexian (various doses)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Milvexian (200 and 500 mg)
Number of subjects: 104
Study: 34728476

Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (metered dose inhaler and nasal saline)
Number of subjects: 203
Study: 36116516

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose quadruple combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose monotherapy
Number of subjects: 0
Study: 32412358

Group type: EXPERIMENTAL
Intervention: EnXtra®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EnXtra® plus caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36011685

Group type: EXPERIMENTAL
Intervention: Differential learning
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-controlled feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 32151512

Group type: EXPERIMENTAL
Intervention: Guided video reflection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Self-regulated learning
Number of subjects: 37

Group type: COMPARATOR
Intervention: Experts (control group)
Number of subjects: 37
Study: 35478433

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (6 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (2 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 33331916

Group type: EXPERIMENTAL
Intervention: Once-weekly oral azithromycin for 48 weeks
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 35331020

Group type: EXPERIMENTAL
Intervention: Headache disorders (Migraine, tension-type headache, other headache)
Number of subjects: 1923

Group type: COMPARATOR
Intervention: Sleep disturbances
Number of subjects: 1923

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 1923

Group type: COMPARATOR
Intervention: Low physical activity
Number of subjects: 1923

Group type: COMPARATOR
Intervention: High screen time exposure
Number of subjects: 1923
Study: 33007106

Group type: EXPERIMENTAL
Intervention: Vitamin D and DHEA (n=19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vitamin D (n=16)
Number of subjects: 35
Study: 37706604

Group type: EXPERIMENTAL
Intervention: Self-guided online psychological intervention for dysfunctional worry
Number of subjects: 670
Study: 33676370

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 220

Group type: COMPARATOR
Intervention: Overall performance of primary reviewers
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Overall adverse events identified
Number of subjects: 220
Study: 35970660

Group type: EXPERIMENTAL
Intervention: Nursing visits by operating room nurses (experimental group)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nursing visits by service nurses (control group)
Number of subjects: 135
Study: 33121891

Group type: EXPERIMENTAL
Intervention: Hypofractionated whole breast irradiation (HWBI) - 40.5 Gy whole breast, 48.0 Gy to surgical bed, 15 fractions over 3 weeks
Number of subjects: 172

Group type: COMPARATOR
Intervention: Accelerated partial breast irradiation (APBI) - 30 Gy delivered in 5 fractions of 6 Gy given on alternate days on the surgical bed
Number of subjects: 172
Study: 33160977

Group type: EXPERIMENTAL
Intervention: 2019 ASGE guidelines
Number of subjects: 744

Group type: COMPARATOR
Intervention: 2010 ASGE guidelines
Number of subjects: 744
Study: 35948376

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) sessions, two times per week during scheduled specialist support classes.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 300
Study: 33963489

Group type: EXPERIMENTAL
Intervention: FOCUS-EC
Number of subjects: 194

Group type: COMPARATOR
Intervention: Online education
Number of subjects: 194
Study: 32843284

Group type: EXPERIMENTAL
Intervention: Hot application
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 36247425

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and Ramipril (D+R)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ramipril (R)
Number of subjects: 33
Study: 33377992

Group type: EXPERIMENTAL
Intervention: Unilateral parotid sparing IMRT
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Bilateral parotid sparing IMRT
Number of subjects: 138

Group type: COMPARATOR
Intervention: Both unilateral and bilateral parotid sparing IMRT
Number of subjects: 138
Study: 35512954

Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow-derived hematopoietic progenitor cells (BMCs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 32171328

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - Structured Material for Therapy (SMART), 6-week intervention
Number of subjects: 163

Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - SMART
Number of subjects: 163
Study: 36238978

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (CM) with delayed mealtimes (1:00 pm–11:00 pm)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Circadian alignment (CA) with mealtimes (9:00 am–7:00 pm)
Number of subjects: 7
Study: 34582721

Group type: EXPERIMENTAL
Intervention: Web-based intervention website including information about breast density, personalized breast cancer risk, chemoprevention, and MRI.
Number of subjects: 995

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 995
Study: 35500966

Group type: EXPERIMENTAL
Intervention: PILATES
Number of subjects: 22

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 22
Study: 35360924

Group type: EXPERIMENTAL
Intervention: Synthetic ECV using specific models in the validation group
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Synthetic ECV using common models in the validation group
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Synthetic ECV in the anemia cohort using specific model
Number of subjects: 1101
Study: 34292205

Group type: EXPERIMENTAL
Intervention: Active tcVNS stimulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study: 35650629

Group type: EXPERIMENTAL
Intervention: Immediate online assessment and subsequent sector-independent treatment coordination (ASSIST)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (waitlist group)
Number of subjects: 400
Study: 32608096

Group type: EXPERIMENTAL
Intervention: Parent training with video modelling (22 sessions)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (standard community treatment)
Number of subjects: 67
Study: 35803894

Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic therapy (IPDT)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: IPDT
Number of subjects: 272

Group type: COMPARATOR
Intervention: ICBT
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 272
Study: 34048587

Group type: EXPERIMENTAL
Intervention: Lower serum ferritin levels (<100 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated serum ferritin and IL-6 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferritin levels above 194 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal ferritin levels for cardiovascular mortality reduction
Number of subjects: 0
Study: 32617701

Group type: EXPERIMENTAL
Intervention: American ginseng 1000 mg per day for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34778937

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (PH6) activated with violet LED (PH6V)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (PH6) activated with blue LED (PH6A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (PH6) without light activation
Number of subjects: 40

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (PH35) - control
Number of subjects: 40
Study: 36056351

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 2482
Study: 33155188

Group type: EXPERIMENTAL
Intervention: Random forest algorithm
Number of subjects: 84977

Group type: COMPARATOR
Intervention: Other machine learning methods (Lasso penalized linear regression, Decision tree, Boosting regression, Bagging regression, Support vectors, Neural network)
Number of subjects: 84977
Study: 34881963

Group type: EXPERIMENTAL
Intervention: Recitation of nursery rhymes (10 sessions, 2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening to nursery rhymes (alphabet-related)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recitation groups (both alphabet-related and unrelated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening groups (non-alphabet-related)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonlinguistic activities)
Number of subjects: 0
Study: 33534516

Group type: EXPERIMENTAL
Intervention: Weekly empathic communication email reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empathic communication quick reference guide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both email reminders and quick reference guide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 0
Study: 33403940

Group type: EXPERIMENTAL
Intervention: 2000 mg of extended-release niacin orally once daily for 24 weeks
Number of subjects: 20
Study: 35301911

Group type: EXPERIMENTAL
Intervention: Motorized Cycle Ergometer (MCE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High Intensity Functional Exercise (HIFE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of MCE and HIFE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 60
Study: 33885776

Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (ciKMC) until 28 days after birth, including promotion and support of skin-to-skin contact and exclusive breastfeeding through home visits.
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Control group (no ciKMC).
Number of subjects: 1950
Study: 32341641

Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg twice daily
Number of subjects: 781

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 781
Study: 32696585

Group type: EXPERIMENTAL
Intervention: Cobimetinib (10 mg single oral dose)
Number of subjects: 0
Study: 35311716

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) with Lumosity software
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional cognitive training
Number of subjects: 39
Study: 32186238

Group type: EXPERIMENTAL
Intervention: Elevated vacuum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Suction suspension
Number of subjects: 12
Study: 616709407

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 34

Group type: COMPARATOR
Intervention: FS‐LASIK
Number of subjects: 34
Study: 34624810

Group type: EXPERIMENTAL
Intervention: Escitalopram (TWE)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Mirtazapine (TWM)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 450
Study: 34193262

Group type: EXPERIMENTAL
Intervention: Combined Lactobacillus reuteri and ω‐3 fatty acid treatment (double-treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (single treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acid (single treatment)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 63
Study: 35704085

Group type: EXPERIMENTAL
Intervention: B‐vitamin supplementation (400 µg folic acid and 500 µg vitamin B12 daily for 2 years)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo (daily for 2 years)
Number of subjects: 191
Study: 33900319

Group type: EXPERIMENTAL
Intervention: Modified alcohol-free beer (16.5 g isomaltulose and 5.28 g resistant maltodextrin per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular alcohol-free beer
Number of subjects: 14
Study: 32719973

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision system and mobile application with expert support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 36187572

Group type: EXPERIMENTAL
Intervention: Nomogram model based on four variables: left atrial diameter, left ventricular ejection fraction, type of atrial fibrillation, systemic inflammation score.
Number of subjects: 485
Study: 33390191

Group type: EXPERIMENTAL
Intervention: Digital intervention to increase adherence to nebuliser treatments, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but the intervention is being tested against standard care in a randomised controlled trial.
Number of subjects: 0
Study: 32037213

Group type: EXPERIMENTAL
Intervention: Traditional fluid management group (TFG)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Oral fluid management group (OFG)
Number of subjects: 130
Study: 35988522

Group type: EXPERIMENTAL
Intervention: 1 % povidone-iodine (PVP-I)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1 % hydrogen peroxide (H2O2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.12 % chlorhexidine (CHX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sodium Chloride 0.9 % (placebo)
Number of subjects: 38
Study: 34273139

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study: 33020951

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash with anti-discoloration system
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash without anti-discoloration system
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 38
Study: 35615299

Group type: EXPERIMENTAL
Intervention: Short course antibiotics (7 days)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Conventional course antibiotics (14 days)
Number of subjects: 604
Study: 33721922

Group type: EXPERIMENTAL
Intervention: Low-cost and culturally acceptable treatment focusing on quality-of-life issues.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrative model of treatment incorporating traditional practices and community support.
Number of subjects: 0
Study: 35027013

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) using the WalkAide® device for 12 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional treatment (AFO/adapted shoes) for 12 weeks
Number of subjects: 25
Study: 33764803

Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme (ACE) inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin‐2 receptor blockers (ARBs)
Number of subjects: 0
Study: 32500675

Group type: EXPERIMENTAL
Intervention: PCSA with sufentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: PCSA with morphine
Number of subjects: 120
Study: 34315492

Group type: EXPERIMENTAL
Intervention: Breastfeeding counseling using a socio‐ecological framework
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard infant feeding information and counseling on immunizations (Control)
Number of subjects: 80
Study: 32476277

Group type: EXPERIMENTAL
Intervention: PF‐SZ‐IFX
Number of subjects: 650

Group type: COMPARATOR
Intervention: IFX‐EU
Number of subjects: 650
Study: 35443108

Group type: EXPERIMENTAL
Intervention: Ivosidenib and azacitidine
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo and azacitidine
Number of subjects: 146
Study: 34102868

Group type: EXPERIMENTAL
Intervention: Active SWT plus a progressive exercise program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo SWT plus a progressive exercise program
Number of subjects: 90
Study: 32404130

Group type: EXPERIMENTAL
Intervention: Daily one-way text message intervention for 6 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care without text message reminders for 6 months
Number of subjects: 94
Study: 33306283

Group type: EXPERIMENTAL
Intervention: Baricitinib plus Remdesivir
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Control (Remdesivir only)
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Baricitinib plus Remdesivir (for patients on high-flow oxygen or noninvasive ventilation)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Control (for patients on high-flow oxygen or noninvasive ventilation)
Number of subjects: 1033
Study: 33228773

Group type: EXPERIMENTAL
Intervention: Hemodynamic algorithm incorporating the respiratory exchange ratio (RER)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard practice hemodynamic care
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Hemodynamic algorithm incorporating the RER
Number of subjects: 350
Study: 35928285

Group type: EXPERIMENTAL
Intervention: PROQOL (Patient-Reported Outcome Quality of Life tool)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: PROQOL
Number of subjects: 383
Study: 33351076

Group type: EXPERIMENTAL
Intervention: Focal Impulse and Rotor Modulation (FIRM) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pulmonary Vein Isolation (PVI) group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FIRM group
Number of subjects: 51

Group type: COMPARATOR
Intervention: PVI group
Number of subjects: 51
Study: 36127661

Group type: EXPERIMENTAL
Intervention: Bumetanide plus chlorthalidone
Number of subjects: 32
Study: 34119811

Group type: EXPERIMENTAL
Intervention: Hypnosis (used in one or several sessions, alone or as an adjunct, reinforced with daily self-hypnosis with or without audio tapes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33351072

Group type: EXPERIMENTAL
Intervention: Low-dose sIPV
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Conventional IPV (cIPV)
Number of subjects: 1422
Study: 32424462

Group type: EXPERIMENTAL
Intervention: AFG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: i‐PRF
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 35605188

Group type: EXPERIMENTAL
Intervention: Lorlatinib (100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice a day)
Number of subjects: 0
Study: 33098995

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 weekly) plus Olaparib (100 mg twice daily for 12 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Paclitaxel plus Carboplatinum (AUC 2 weekly for 12 weeks)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Olaparib
Number of subjects: 107
Study: 32073673

Group type: EXPERIMENTAL
Intervention: Iron status assessment (haemoglobin concentration, serum iron, serum ferritin, transferrin saturation)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Stage II and III iron depletion
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Serum ferritin as a biomarker
Number of subjects: 170
Study: 35861805

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional metric-modified Rankin Scale score 0-2
Number of subjects: 0
Study: 34278665

Group type: EXPERIMENTAL
Intervention: Protaper Universal (PTU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reciproc Blue (RB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 32159519

Group type: EXPERIMENTAL
Intervention: MeMo Web app (active MeMo group, n=9)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MeMo Web app (nonactive MeMo group, n=13)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not using MeMo)
Number of subjects: 46
Study: 33855585

Group type: EXPERIMENTAL
Intervention: Sorafenib monotherapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High IL-6 levels
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High IL-8 levels
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Baseline IL-6 cut-off value of 8.58 pg/mL
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Baseline IL-8 cut-off value of 57.9 pg/mL
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IL-6 and IL-8 as independent predictors of OS
Number of subjects: 47
Study: 33408308

Group type: EXPERIMENTAL
Intervention: Docetaxel/Nedaplatin (60/80 mg/m2/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Docetaxel (70 mg/m2/day)
Number of subjects: 36
Study: 32621073

Group type: EXPERIMENTAL
Intervention: Cabergoline (dopamine D2 agonist)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35889902

Group type: EXPERIMENTAL
Intervention: ONS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ONS + EX
Number of subjects: 24
Study: 35792744

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (10 µM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (30 µM)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (0.8 dS m‐1 ECw)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Salt stress (1.6, 2.4, and 3.2 dS m‐1 ECw)
Number of subjects: 3
Study: 32692751

Group type: EXPERIMENTAL
Intervention: Protein-calorie food supplement offered daily to pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years.
Number of subjects: 1826
Study: 94188401

Group type: EXPERIMENTAL
Intervention: Assessment and intervention protocol for fall prevention and mobility improvement
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Assessment and intervention protocol
Number of subjects: 31